MarkMMoasserMD

Oncology • San Francisco, CA

Professor, Medicine, UCSF School of Medicine

Join to view full profile

Dr. Moasser is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Moasser's full profile

Already have an account?

Office
1825 fourth street
San Francisco, CA 94158
Phone+1 415-353-7070

Fax+1 415-353-7021

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1991 - 1996
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1988 - 1991
Tufts University School of MedicineClass of 1988

Certifications & Licensure

CA State Medical License 2004 - 2025
NY State Medical License 1989 - 2005
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Elected Member The American Society for Clinical Investigation, 2008

Clinical Trials

Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors Start of enrollment: 2006 Feb 01
Completed
Phase 1
Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2 Start of enrollment: 2007 Aug 01
Completed
Phase 1
Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies Start of enrollment: 2012 Mar 27
Completed
Phase 1, Phase 2

Publications & Presentations

PubMed

A phase Ib/II study of eribulin in combination with cyclophosphamide in patients with advanced breast cancer.
Ozge Gumusay, Laura A Huppert, Mark Jesus M Magbanua, Chiara A Wabl, Michael Assefa
Breast Cancer Research and Treatment. 2024-01-01
10 citations
Molecular Pathways and Mechanisms of HER2 in Cancer Therapy.
Kanwal P S Raghav, Mark M Moasser
Clinical Cancer Research. 2023-07-05
17 citations
A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFcolorectal tumors.
Ana Ruiz-Saenz, Chloe E Atreya, Changjun Wang, Bo Pan, Courtney A Dreyer
Nature Cancer. 2023-02-01

Abstracts/Posters

Development of a Pathway-Directed Drug Screen Platform for Cutaneous T Cell Lymphoma Using Patient-Derived Xenograft Models
Mark Moasser, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Press Mentions

Trial Confirms That Perjeta Extends Survival in Metastatic Breast CancerSeptember 28th, 2014
Solving the Mystery of a Stubborn, and Common, Cancer GeneMarch 5th, 2022

Grant Support

Understanding Resistance To HER Family Tyrosine Kinase InhibitorsNational Cancer Institute2007–2011
Adhesion Signaling By A Novel Mitotic Substrate Of SRCNational Cancer Institute2005–2009
Pilot Studies To Develop Probes For In Vivo Imaging Of P13k/Akt Pathway ActivityNational Cancer Institute2007–2008